ORP-110
ORP-110 is a discovery-stage, metabolically-stable P2Y receptor ligand.
- About
- Science
- Pipeline
- Licensing
-
Newsroom
-
News and Press Releases
- OrphoMed, Inc. Announces Positive Phase 2 Results for ORP-101 100 mg Once-Daily Dose in IBS-D Patients
- OrphoMed’s ORP-101 Passes Second Planned Interim Analysis in Phase 2 Study of Treatment for IBS-D Patients
- OrphoMed Passes First Interim Analysis in Phase 2 Study of Treatment for IBS-D Patients
- OrphoMed Resumes Recruitment for Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D
- OrphoMed Pauses Recruitment for Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D
- OrphoMed to Present Phase 1 Results of ORP-101 at Digestive Disease Week 2020
- OrphoMed Initiates U.S. Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D
- OrphoMed to Present at the 2019 BIO Investor Forum
- OrphoMed Announces Formation of Scientific Advisory Board
- FDA Grants Fast Track Designation for OrphoMed’s ORP-101 for Treatment of IBS-D
- OrphoMed Appoints Gary M. Phillips, M.D. as President and Chief Executive Officer
- OrphoMed featured in Wall Street Journal article on intestinal-focused startups
- OrphoMed to Present at the 2018 BIO CEO & Investor Conference
- OrphoMed Appoints Mark Sostek, M.D. as Chief Medical Officer
- OrphoMed to Present at the 2017 BIO Investor Forum
- OrphoMed Secures $39 Million Series A Financing Round
- FierceBiotech: Takeda and NEA back $39M series A for GI biotech OrphoMed
- OrphoMed Announces Late-breaking Plenary Session Presentation of New Preclinical Data for ORP-101 in IBS-D at Digestive Disease Week 2017
- Events and Presentations
-
News and Press Releases
- Contact